Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia

Table 2

Characteristics of the population.

Variable		Frequency (%)
Age (median)	68 years (50–81)
Sex	Female	4 (40%)
	Male	6 (60%)
Diagnosis	Diffuse large B-cell lymphoma	2 (20%)
	Follicular lymphoma	3 (30%)
	Waldenström’s disease	2 (20%)
	Marginal zone lymphoma	2 (20%)
	Mantle cell lymphoma	1 (10%)
Line of treatment	First-line	7 (70%)
	Second-line	3 (30%)
Grade of reaction	Mild	2 (25%)
	Moderate	1 (12.5%)
	Severe	4 (50%)
	Life-threatening	1 (12.5%)